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1. Introduction 
A tumor is an abnormal mass of cells, the growth of which exceeds that of the normal 
tissue. Although most of the skin tumors retain a resemblance to the normal tissues from 
which they arise, they can show variations in their structure which cause difficulties in 
establishing pathological diagnosis. In contrast to benign skin tumors, which in most 
cases remain at the site of their origin and form compact mass of tumor cells, malignant 
tumors are composed of cells with the ability to invade the basement membrane and 
metastasize to other organs through blood and lymphatic vessels. Moreover, malignant 
tumors are often characterized by a more rapid growth and less differentiation, which 
histologically is characterized by a higher mitotic index and cellular and nuclear 
pleomorphism (Quinn & Perkins, 2010). Differentiation between benign and malignant 
skin tumors is one of important questions in terms of diagnostics, prognosis and 
treatment of the skin lesions. 
Recently, a variety of molecular markers were shown to be promising in correlation with 
aggressive and invasive behavior of skin cancers. These involve aberrant expression of p53 
(Verdolini et al., 2001), increased expression of transcription factors (Keehn et al., 2004), 
metalloproteinases (MMPs) (Verdolini et al., 2001), and proliferation markers mib1, Ki-67 
(Oh & Penneys, 2004), stem cell markers c-kit, p63 (Laskin & Miettinen, 2003), increased 
phosphorylation of regulatory proteins and up-regulation of receptors of growth factors 
(Weigelt et al., 2005). 
Tumor growth and invasiveness is accompanied by altered cell-cell communications. Thus, 
aggressive cancers are associated with decreased expression of E-cadherin which correlates 
with increased expression of desmosomal junction protein desmoglein (Kurzen et al., 2003) 
and N-cadherin (Gloushankova, 2008; Berx & van Roy, 2009).  
T-cadherin, a non-classical member of cadherin family, was also suggested to play a role in 
cancer progression (Andreeva & Kutuzov, 2010; Philippova et al., 2009). 
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2. T-cadherin structure and intracellular signaling 
T-cadherin is an atypical member of the cadherin superfamily. While possessing the general 
extracellular structure of classical cadherins, T-cadherin lacks transmembrane and cytoplasmic 
domains and is anchored to the plasma membrane by a glycosylphosphatidylinositol (GPI) 
moiety (Ranscht & Dours-Zimmermann, 1991). Since transmembrane and cytoplasmic 
domains of classical cadherins are generally recognized to be crucial in maintaining stable 
cell-cell contacts (Gumbiner, 2005), it is considered that the main function of T-cadherin is 
not cell-cell adhesion (Rubina et al., 2005a; Rubina & Tkachuk, 2004). Like other GPI-
anchored proteins, T-cadherin is located in lipid rafts/caveolae (Philippova et al., 1998). 
Lipid rafts are cholesterol and sphingolipid rich domains of plasma membrane, which 
contain GPI-anchored proteins and signal transduction molecules such as Src-family kinases 
(Brown & London, 2000; Maxfield, 2002). 
Indeed, T-cadherin was shown to be involved in regulation of cell adhesion, migration, 
proliferation and survival via activation of intracellular signaling. By using dominant 
negative and constitutively active forms of Rho, Rac and Cdc42 it was shown that Rho 
GTPases act downstream of T-cadherin and the activation of Rac1 and Cdc42 GTPases 
results in increased phosphorylation of LIMK1 kinase, actin and microtubule cytoskeleton 
rearrangements, activation of endothelial cell migration and increased permeability of 
endothelial cell monolayer (Philippova et al., 2005; Semina et al., 2009). Overexpression of 
T-cadherin in endothelial cells led to higher phosphorylation levels for 
phosphatidylinositol-3-kinase (PI3K) target Akt and mTOR target p70S6K involved in 
survival pathway in endothelial cells, but lower levels for p38MAPK (death pathway) 
(Joshi et al., 2005).  In line with that, it was shown that T-cadherin mediated activation of 
PI3K/Akt/GSK3β signaling which protects endothelial cells from oxidative stress-
induced apoptosis (Joshi et al., 2005). The effects of T-cadherin on Akt activation and 
survival require T-cadherin interacting partner Grp78, which is also known to be up-
regulated in cancers (Andreeva et al., 2010; Philippova et al., 2008). High molecular 
weight adiponectin activates NF-kB and inhibits endothelial cell apoptosis suggesting that 
T-cadherin binding to adiponectin could prevent apoptosis of endothelial cells in tumor 
vessels (Adachi et al., 2006). Overexpression of T-cadherin in human aortic smooth muscle 
cells and in HUVECs increases cell proliferation (Ivanov et al., 2004). However, T-
cadherin overexpression in HUVECs also results in an increased number of multinuclear 
cells, whereas its downregulaion results in increased amount of cells with multiple 
centrosomes (Andreeva et al., 2009). Stimulation of vascular endothelial cells and T-
cadherin overexpressing HEK293 cells with plasma low density lipoproteins 
demonstrated the T-cadherin-induced signaling involving phospholipase C and IP3 
formation, intracellular Ca2+ mobilization, activation of tyrosine kinases Erk 1/2, and 
nuclear translocation of NF-kB (Kipmen-Korgun et al., 2005; Rubina et al., 2005b).  
However, in contrast to endothelial cells, overexpression of T-cadherin in C6 glioma 
(Huang et al., 2003) hepatocellular carcinoma cells (Chan et al., 2008), in immortalized 
keratinocytes (Mukoyama et al., 2005) and in p53(-/-) mouse embryonic fibroblasts (Chan 
et al., 2008) suppresses proliferation by delaying the G2/M phase progression. In 
hepatocellular carcinoma cells T-cadherin expression also increases sensitivity to TNF-
induced apoptosis (Chan et al., 2008). Hence, in different studies T-cadherin was shown to 
be involved in regulation of proliferation, apoptosis and angiogenesis in normal tissues 
and tumor growth. 
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3. T-cadherin mediates homophilic interaction and vessel repulsion in 
angiogenesis 
It is worth noting that in most experimental studies, the main attention is usually paid to the 
expression of T-cadherin in endothelial cells of the vessels while the role of T-cadherin 
expression by stromal cells in neoangiogenesis is rarely considered. In contrast, we used the 
Matrigel model, where Matrigel plugs containing L929 fibroblasts (control or overexpressing 
T-cadherin) where injected subcutaneously into nu/nu mice. In this settings, migrating 
endothelial cells, naturally expressing T-cadherin, contacted with T-cadherin positive 
fibroblasts and this interaction resulted in suppressed blood vessel growth. This effect of T-
cadherin was dependent upon the concentration of T-cadherin expressing cells injected into 
the Matrigel. Moreover, small vessels and capillaries which invaded the Matrigel plug with 
high level of T-cadherin, did not express T-cadherin. Conceivably, high expression of T-
cadherin inhibited the growth of the blood vessels. Furthermore, T-cadherin overexpression in 
the stroma regulated qualitative composition of blood vessels infiltrating the tissue either by 
negative guiding of T-cadherin expressing vascular endothelial cells or by downregulation of 
T-cadherin expression in the growing vessels, or both (Rubina et al., 2007).  
It was shown that the general mechanism of T-cadherin mediated repulsion could involve 
homophilic T-cadherin interaction and contact inhibition as it was revealed for the growth of 
axons in the embryonic nervous system (Fredette et al., 1996). The same mechanism was 
shown to be responsible for regulation of the trajectory of the growing vessels. The first set of 
evidence came from in vitro experiments utilizing immobilized N-terminal EC1 domain of T-
cadherin (Ivanov et al., 2004), which was responsible for homophilic T-cadherin interaction of 
contacting cells (Rubina et al., 2007). In vitro in Boyden chamber, ring aorta and capillary tube 
assays, we have shown that migration of endothelial cells, which endogenously express T-
cadherin (Philippova et al., 2003), was inhibited by immobilized EC1 domain.  
Thus, the most likely mechanism of T-cadherin-mediated suppression of blood vessel 
ingrowth is the interaction between T-cadherin molecules on endothelial and surrounding 
cells. This interaction leads to initiation of intracellular signaling cascades, which 
presumably are similar to ephrin’s signaling, followed by cell-cell repulsion. 
4. T-cadherin and tumor growth and vascularization 
It has been proposed that T-cadherin functions as a tumor suppressor factor and its 
downregulation due to allelic loss or hypermethylation in the promoter region of the gene 
or some other reasons is related to tumor growth and metastasis in certain cancers (Takeuchi 
et al., 2002b; Andreeva & Kutuzov, 2010). Downregulation of T-cadherin was shown to be 
associated with malignant phenotype and tumorigenecity in breast (Riener et al., 2008), lung 
(Sato et al., 1998), and gallbladder cancers (Adachi et al., 2009). However, in other cancers 
such as ovarian, endometrial (Widschwendter et al., 2004; Suehiro et al., 2008) and 
osteosarcoma (Zucchini et al., 2004) T-cadherin decreased expression correlated positively 
with patient survival. T-cadherin overexpression was found to be a common feature of 
human invasive hepatocellular carcinomas (Riou et al., 2006) and high grade astrocytomas, 
where it was associated with malignant transformation of astrocytes. Hetezygosity for NF1 
(neurofibromatosis 1) tumor suppressor resulting in reduced attachment and spreading and 
increased motility also coincided with upregulated T-cadherin expression (Gutmann et al., 
2001).  
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Data on non-melanoma skin cancers and related premalignant lesions are also contradicting. 
In normal skin T-cadherin is expressed in keratinocyte basal cell layer (Zhou et al., 2002). In 
actinic keratosis T-cadherin expression is pronounced on the atypical keratinocytes, while in 
Bowen disease expression of T-cadherin varies and is in general weaker than in normal skin 
(Pfaff et al., 2010). Expression of T-cadherin is reduced in psoriasis (Zhou et al., 2003), is 
absent in invasive cutaneous squamous cell carcinoma due to aberrant methylation and 
gene deletion (Takeuchi et al., 2002a) and is down-regulated in basal cell carcinoma of the 
skin (Takeuchi et al., 2002b).  
While in some studies the authors investigated the correlation between the hypermetylation 
of T-cadherin promoter or allelic loss, the others addressed the effect of T-cadherin re-
expression on the malignant properties of cancer cells upon injection of cells in vivo in 
mouse models. Melanoma cells (Kuphal et al., 2009), hepatocellular carcinoma cells (Chan et 
al., 2008) and human breast carcinoma cells (Lee et al., 1998) showed a reduced tumor 
growth upon re-expression of T-cadherin. The transfection of mammary gland cells with 
cDNA of T-cadherin resulted in suppression of the cell proliferation in culture, which was 
also accompanied by transformation of the cancer cells from the invasive to the normal 
phenotype  (Lee, 1996). The overexpression of T-cadherin in the neuroblastoma cells led to 
the suppression of invasion of the cells and the loss of their ability to respond to the addition 
of epidermal growth factor (EGF) with increased proliferation (Takeuchi et  al., 2000). The 
overexpression of T-cadherin  in the cells of glioma C6 was accompanied by the decrease of 
cell migration and suppression of the growth and proliferation in those cells due to blockade 
of the cell cycle on the stage G2 (Huang et al., 2003). In immortalized keratinocyte cell lines 
derived from squamous cell carcinoma forced over-expression of T-cadherin resulted in 
decreased cell proliferation (Mukoyama et al., 2005). 
These in vivo and in vitro data suggest that T-cadherin could be an endogenous negative 
regulator of keratinocyte proliferation. However, proliferating basal keratinocytes of the 
epidermis also express T-cadherin, leading to the conclusion that the role of T-cadherin in 
regulation of tumor cell growth and invasion is more complex.  
Angiogenesis is necessary for tumor growth, invasion and metastases, therefore it has 
prognostic value and can be a therapeutic target. Angiogenesis is the process in which 
endothelial cells divide and migrate to form new capillaries, which support the continued 
growth of tumor through blood flow (Hasan et al., 2002; Sasano et al., 1998). Cancer-induced 
angiogenesis in general results from increased expression of angiogenic factors by tumor 
and/or stromal cells such as VEGF-A or decreased expression of anti-angiogenic factors, or a 
combination of both events (Hasan et al., 2002). Numerous authors reported that angiogenesis 
plays an important role in tumor progression and metastasis of the great majority of human 
solid tumors (Hasan et al., 2002; Offersen et al., 2002; Rubin et al., 1999; Vieira et al., 2004). 
During tumor angiogenesis, a certain sequence of events occurs resulting in directional 
migration of endothelial cells through the basement membrane and perivascular stromal cells 
toward angiogenic stimuli produced by tumor cells. In normal angiogenesis after endothelial 
cell migration and proliferation mural cells (smooth muscle cells and pericytes) enable 
stabilization of the nascent vessels. However, the newly formed tumor vessels are usually thin-
walled capillaries or sinusoids with little more than an endothelial lining stabilized by a 
basement membrane and are susceptible to spontaneous hemorrhage and thrombosis 
(Carmeliet, 2000; Jain & Carmeliet, 2001; Yancopoulos et al., 2000).  
Increasing evidence supports the essential role of VE and N-cadherin in the assembly of the 
vascular network. The adhesive properties of these cadherins are important for their 
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angiogenic function, as far as they control both endothelial cell–cell interactions and the 
interaction of endothelial cells with stroma. The application of antibody against N-terminal 
repeat of VE-cadherin established this cadherin as a possible target for inhibiting 
angiogenesis in tumors (Cavallaro et al., 2006). 
It is quite possible that T-cadherin affects carcinogenesis not only due to its aberrant 
expression in cancer cells, but also because it affects tumor neovascularization. Thus, in 
normal blood vessels T-cadherin is expressed in endothelial and mural cells (smooth muscle 
cells and pericytes) (Ivanov et al., 2001). However, as shown in numerous studies, T-
cadherin expression is altered in tumor vessels: in Lewis carcinoma lung metastasis and F9 
teratocarcinoma, PC-3 prostate cancer, in A673 rhabdomyosarcoma the expression of Т-
cadherin is upregulated on endothelial cells of the blood vessels penetrating the tumor (Riou 
et al., 2006; Wyder et al., 2000), while no T-cadherin could be detected in the blood vessels of 
B16F10 melanoma lung metastasis (Wyder et al., 2000). Using mouse mammary tumor virus 
(MMTV)-polyoma virus middle T (PyV-mT) transgenic model with inactivated T-cadherin 
gene it was shown that T-cadherin deficiency limits mammary tumor vascularization and 
reduces tumor growth (Hebbard et al., 2008).   
In tumor neovascularization of hepatocellular carcinoma (НСС) T-cadherin is also 
upregulated in intratumoral capillary endothelial cells, whereas in surrounding tumor tissue 
as well as in normal liver nо Т-cadherin could be detected (Adachi et al., 2006). The increase 
in Т-cadherin expression in endothelial сеlls of НСС was shown to соrrеlаtе with tumor 
progression (Adachi et al., 2006). The involvement of T-cadherin in melanoma angiogenesis 
was demonstrated using an in vitro tumor spheroid model in co-culture with endothelial 
cells where T-cadherin upregulation in endothelial cells potentiated intratumoral 
angiogenesis (Ghosh et al., 2007). These data indicate that the contradictory results on tumor 
progression could be due to the complex cancer, stromal and endothelial cell intracellular 
interactions inside the growing tumor. The possible mechanism underlying the function of 
T-cadherin in angiogenesis could be the regulation of the trajectory of the growing blood 
vessels, thus T-cadherin acts as a navigating receptor (Rubina et al., 2007).  
A diversity of navigating receptors has been already identified and shown to be involved in 
regulation of angiogenesis during embryogenesis and regeneration. These include 
semaphorins and their receptors (plexins and neuropilins), neutrins and their receptors 
(DCC/neogenine and Unc5), slit-ligands and their receptors Robo, and ephrins and their 
receptors (Adams et al., 1999; Weinstein, 2005). It is also known that ephrins and their 
receptors are navigation molecules regulating the trajectory of migration and differentiation 
of the cells in cardiovascular system (Adams et al., 1999); they have also been linked to the 
regulation of tumor angiogenesis (Ogawa et al., 2000). 
To address the influence of T-cadherin overexpression in tumor cells on the ingrowth of the 
blood vessels into the tumor we used in vivo model of chorioallantoic membrane. For that 
the melanoma B16F10 cells overexpressing T-cadherin were injected under the 
chorioallantoic membrane in chick embryo, thus creating the microenvironment with high 
content of T-cadherin. This resulted in the reduction of the amount of blood vessels growing 
into the tumor with high expression of T-cadherin in comparison to the control (Yurlova et 
al., 2010). Presumably, the homophilic interaction and “repulsion” between molecules of T-
cadherin on the surface of endothelial cells and tumor cells occurred at the contact of 
migrating endothelial cells which endogenously express T-cadherin with the tumor cells of 
melanoma, thereby resulting in the suppression of angiogenesis.  
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5. Stroma plays an active role in tumor growth and progression 
In normal tissues stromal fibroblasts are responsible for the synthesis, deposition and 
remodeling of the extracellular matrix, as well as for the production of the soluble paracrine 
factors that regulate (promote or inhibit) cell proliferation, morphology and migration, 
survival and apoptosis (Klopp et al., 2011; Tlsty & Coussens, 2006).  Tumor fibroblasts are 
derived, in part, from mesenchymal stem cells that may be recruited regionally or from 
circulating populations from the bone marrow (Mishra et al., 2008; Spaeth et al., 2008). 
Tumor fibroblasts isolated from malignant tissues exhibit altered phenotypes, mostly 
because of the aberrant production of the extracellular matrix proteins and growth factors 
(Bauer et al., 1979; Knudson et al., 1984; Tlsty & Coussens, 2006), disorganized patterns of 
growth, and enhanced proliferation (Rasmussen & Cullen, 1998; van den Hooff, 1988). Such 
phenotypes promote tumor progression (Klopp et al., 2011).  
Tissue combination experiments using normal human prostatic epithelial cells with stromal 
cells obtained from prostatic adenocarcinoma demonstrated an interaction that limited growth 
potential of the epithelial cells while re-establishing their ability to form ductal structures 
resembling prostatic intraepithelial neoplasia. Engrafting of the stromal cells isolated from 
tumors together with immortalized human prostatic epithelial cells led to tumor formation 
exceeding by 500 fold the weight of control grafts (Olumi et al., 1999). Remarkably, isolation of 
pure human epithelial cell populations from these tumors and subsequent grafting into 
animals demonstrated that the epithelial cells were then able to form tumors while tumor 
fibroblasts presence and activity was no longer necessary (Olumi et al., 1999). Histological 
analysis of these tumors showed their characteristic features of malignant neoplasms with 
enhanced cell proliferation, reduced apoptosis, active angiogenesis, and genomic instability. 
Tumor fibroblasts isolated from human tumors also facilitate the growth of human breast and 
ovarian cancers when co-injected into immunosuppressed mice (Orimo et al., 2005).  
These studies demonstrate that tumor stromal cells can produce oncogenic signals that can 
transform normal epithelial cells and induce them towards malignant state, thus 
establishing an active role of stromal cells in tumorigenic processes. Reciprocally, when 
placed in co-culture, tumor cells can directly induce stromal cells to convert into smooth 
muscle actin positive cells and express vimentin and stromal derived factor 1 (SDF-1), 
common to cancer associated fibroblasts. Transforming growth factor β (TGF often 
produced by tumor cells was shown to induce conversion of adjacent stromal cells into 
smooth muscle actin expressing cells (Mishra et al., 2008; Spaeth et al., 2009; Tlsty & 
Coussens, 2006).  
Thus, stromal cells together with cancer cells regulate tumor neoangiogenesis, in part, by 
local changes in the balance between soluble and insoluble molecules that elicit either pro- 
or antiangiogenic effects (Cavallaro et al., 2006; Takeuchi & Ohtsuki, 2001; Wyder et al., 
2000). Mesenchymal stromal cells are known to secrete different proangiogenic factors, such 
as vascular endothelial growth factor (VEGF-A), fibroblast-derived growth factor (FGF), 
platelet-derived growth factor (PDGF), and SDF-1 (Efimenko et al., 2010; Rubina et al., 2009). 
These cytokines promote endothelial and smooth muscle migration and proliferation at the 
tumor site, facilitating angiogenesis (Kinnaird et al, 2004; Potapova et al., 2007). Other 
growth factors responsible for mesenchymal stromal cell effects on tumor vasculature 
include hepatocyte growth factor (HGF), cyclooxygenase, insulin-like growth factor 1 (IGF-
1), PDGF-a, and TGF (Beckermann et al., 2008). 
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6. T-cadherin expression in precancerous lesions and malignant neoplasm of 
the skin 
To define the role of T-cadherin in the pathogenesis of skin lesions we performed a 
comparative study of T-cadherin expression in normal skin samples, in non-melanoma skin 
cancer and related premalignant lesions. Cryosections of human skin biopsies from healthy 
donors, patients with keratoacanthoma in growth and stabilization stages, patients with 
keratosis, patients with superficial, nodular and infiltrative types of basal cell carcinoma, 
patients with basosquamous cell carcinoma and patients with squamous cell carcinoma 
were immunostained with antibodies against T-cadherin and vascular cell markers and 
analysed using fluorescent microscope.  
6.1 Immunofluorescent staining 
Human skin biopsies from 6 healthy donors, 10 patients with keratoacanthoma, 3 patients 
with keratosis, 30 patients with basal cell carcinoma, 5 patients with basosquamous cell 
carcinoma and 5 patients with squamous cell carcinoma were obtained from Dermatology 
Department of First Moscow State Medical University. Consequent cryosections of skin 
biopsies (7m thick) were fixed in 4% paraformaldehyde (PRS Panreac, Spain) for 10 min. 
After several washes with phosphate buffer saline (PBS, Sigma-Aldrich, USA ) sections were 
incubated in PBS/0.1% bovine serum albumine (BSA, Sigma-Aldrich, USA) containing 10% 
normal donkey serum (Sigma-Aldrich, USA) to block non-specific binding of antibodies. 
This was followed by incubation in a mixture of primary antibodies against T-cadherin 
(rabbit anti-human, ProSci, USA) and endothelial cell markers - vWF (Von Willebrand 
factor, mouse anti-human, BD Biosciences, USA ) or CD31 (mouse anti-human, BD 
Biosciences, USA), or marker of smooth muscle cells and pericytes - actin (rabbit anti-
human, Epitomics, USA) for 1 hour and subsequent extensive washing in PBS. Then sections 
were incubated in a mixture of secondary antibodies Alexa488-conjugated donkey anti-
mouse and Alexa594-conjugated donkey anti-rabbit or Alexa488-conjugated donkey anti-
rabbit and Alexa594-conjugated donkey anti-mouse (Molecular Probes, USA) (1g/ml in 
PBS). Cell nuclei were counterstained with DAPI (Molecular Probes, USA). Sections were 
mounted in Vectashield mounting media (Vector Laboratories Inc., USA). For negative 
controls mouse or rabbit non-specific IgGs were used in appropriate concentration. Images 
were obtained using Zeiss Axiovert 200M microscope equipped with CCD camera AxioCam 
HRc and Axiovision software (Zeiss, Germany) and further processed using Adobe 
PhotoShop software (Adobe Systems, USA).  
6.1.1 Normal skin 
In normal skin the strongest T-cadherin expression was found in basal keratinocytes, 
stromal cells and in all blood vessels located in the underlying derma as observed by 
staining with antibody against endothelial marker vWF and marker of smooth muscle cells 
and/or pericytes - actin (Fig.1). 
This data are in line with the previous observations (Takeuchi et al., 2002b). And yet, for the 
first time we have identified T-cadherin expression in hair follicles and sebaceous glands 
(Fig.1). In contrast to other studies (Zhou et al., 2002; Pfaff et al., 2010), we have found T-
cadherin expression in the suprabasal layers of epidermal keratinocytes, although weaker 
than in the basal layer.  
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Fig. 1. Double immunofluorescent staining of normal skin samples with antibodies against T-
cadherin (red) and vWF (green) (A, E) or vWF (red) and actin (green) (C). Figures A, B, C 
represent parallel frozen sections of the same sample. T-cadherin expression was detected in 
basal keratinocytes, suprabasal layers, stromal cells and in hair follicles and sebaceous glands. 
Nuclei were counterstained with DAPI (blue). Figure B depicts phase contrast image.  Uniform 
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expression of T-cadherin in small and large blood vessels was noted (yellow), colocalization of 
T-cadherin and vWF is showed by the arrow. Stabilized vessels were located in derma and 
were double positive for vWF and actin; stromal cells were also actin-positive (C). Bars, 
100 m. Figure D represents the diagram explaining strong T-cadherin expression in basal cell 
layer (red) and stromal cells, moderate T-cadherin expression (pink) in suprabasal layers and 
T-cadherin expression in all vWF-positive blood vessels (yellow). F figure legend. 
Premalignant epithelial lesions are conditions that have certain clinical and histopathological 
features and are associated with an increased risk of cancer development (Quinn and Perkins, 
2010). Premalignant lesions frequently have many histopathological changes in common with 
invasive cancers; however, this doesn’t imply that the premalignat lesions will change into 
neoplastic process. Therefore, it is important to identify the diagnostic markers which will 
allow better accuracy in diagnostics of premalignant lesions and cancer and their treatment.  
6.1.2 Psoriasis  
Psoriasis is a chronic condition that causes keratinocytes proliferate much faster that in 
normal skin and move to the skin surface forming sharply demarcated erythematous plaques 
or thick patches (Godic, 2004). Such pathology reflects the abnormal epidermal keratinocyte 
proliferation and differentiation and delayed apoptosis. Histological characteristics of 
psoriasis are hyperkeratosis, parakeratosis, acanthosis of the epidermis, tortuous and dilated 
capillary vessels and an inflammatory infiltrate composed mainly of lymphocytes, which is 
located in the upper dermis. The underlying mechanism of increased keratinocyte growth 
remains controversial. It is considered to be genetically determined and have a strong 
autoimmune component implicating activated T-lymphocytes and excessive production of 
inflammatory cytokines (Godic, 2004).  However, psoriasis is unique because it exhibits 
excessive but controlled keratinocyte proliferation. Recent study demonstrated that there is 
downregulation of T-cadherin expression in epidermal keratinocytes in psoriatic samples 
compared to normal skin. The immunostaining against T-cadherin in psoriasis vulgaris as 
shown in this paper is restricted to the keratinocyte basal cell layer (Zhou et al., 2003). In 
contrast, our results indicate that T-cadherin expression in psoriatic skin is comparable to 
normal skin (Fig.1 and Fig.2). Our data have been acquired at a fixed exposure period and the 
intensity of the immunifluorescent staining in both types of samples was the same. In 
psoriatic skin T-cadherin expression was found in all keratinocyte cell layers with a stronger 
expression in basal keratinocytes than in hyperproliferating suprabasal layers, also in stromal 
cells and in all blood vessels located in the underlying derma. Strikingly, in contrast to 
normal skin samples, in psoriatic skin the abnormal location of blood vessels within the 
epidermal layer was also found (Fig.1 and Fig.2). Noteworthy, these vessels, as verified by 
endothelial marker vWF, also uniformly expressed T-cadherin (Fig.2). 
6.1.3 Actinic Keratosis (AK) 
AK is a common sun-induced skin lesion. Actinic keratosis is usually characterized as scaly 
or keratotic papules with a diffuse erythematous base, usually less than 1-2 cm in diameter. 
Historically, AK has been described as a pre-cancerous lesion (Quinn and Perkins, 2010). 
Many authors consider these lesions as pre-malignant epithelial tumors that have the 
potential to develop into squamous cell carcinoma (SCC) (Epstein, 2004; Jorizzo et al., 2004; 
Yu et al., 2003). However, a number of studies indicate that progression of AK to invasive 
SCC may be rather exception than a rule and that AKs can undergo spontaneous regression  
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Fig. 2. Double immunofluorescent staining of psoriatic skin sample with antibodies against 
T-cadherin (red) and vWF (green) (A). Nuclei were counterstained with DAPI (blue). Figure 
B represents hematoxylin staining of the parallel section. Strong T-cadherin expression was 
found in basal keratinocytes, in hyperproliferating suprabasal layers, stromal cells and 
blood vessels located in the underlying derma and within the epidermal layer. Uniform 
expression of T-cadherin in small and large blood vessels was observed (yellow), 
colocalization of T-cadherin and vWF is showed by the arrows. Bars, 100 m. The diagram 
(C) explaining strong T-cadherin expression in basal cell layer (red), moderate T-cadherin 
expression in suprabasal layers and stromal cells (pink) and T-cadherin expression in all and 
all vWF-positive blood vessels (yellow). 
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(as cited in Quinn & Perkins, 2010). Other authors have stated that there is no patho-
biological difference between AK and SCC and that AK itself represents SCC variant 
(Ackerman & Mones, 2006; Freeman et al., 1984; Lebwohl et al., 2004). Without treatment, 
AK can develop into invasive SCC and has the potential to metastasise and cause death.  
 
 
Fig. 3. Double immunofluorescent staining of actinic keratosis sample with antibodies 
against T-cadherin (red) and vWF (green) (A) or vWF (green) and actin (red) (C). Nuclei 
were counterstained with DAPI (blue). Figure B represents hematoxylin staining of the 
parallel section. T-cadherin expression was observed in basal keratinocytes, including 
suprabasal layers, with a more pronounced staining in the basal cell layer. Not all blood 
vessels as detected by vWF staining were positive for T-cadherin. Colocalization of T-
cadherin and vWF is shown by the arrows, blood vessels which do not express T-cadherin - 
by arrowheads. Stabilized vessels were located in derma and were double positive for vWF 
and actin; (C). Bars, 100 m. The diagram (D) explaining strong T-cadherin expression in 
basal cell layer (red), moderate T-cadherin expression in suprabasal layers and stromal cells 
(pink). Blood vessels expressing T-cadherin and vWF are shown in yellow, blood vessels 
with no T-cadherin expression are shown in green. 
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In AK the boundary between unaffected and affected epidermis is sharp. The affected zone 
grows under the normal epidermis and around the ductal epithelium. Histologically, AK is 
characterized by the presence of atypical keratinocytes at the epidermal basal cell layer, 
which in advanced lesions may extend into the entire epidermis (Röwert-Huber et al., 2007). 
There is epidermal hypertrophy with hyperkeratosis and parakeratosis. The basement 
membrane is intact but basaloid cells may form multiple buds. Within the epidermis there 
may be a simple dysplasia or a range of abnormalities. The underlying papillary vessels are 
irregularly increased. There is degeneration of dermal collagen and deposition of material 
staining like elastin in the upper half of the dermis (Quinn & Perkins, 2010). In addition to 
the epidermal changes, a common feature of AK is the presence of a chronic inflammation in 
the papillary dermis of the abnormal epidermis (Pinkus et al., 1963). 
Figure 3 presents the hematoxylin and immunofluorescent stainings of AK sections with 
antibody against T-cadherin, vWF and actin. The lesion is characterized by the presence of 
atypical keratinocytes at the epidermal basal cell layer and loss of orderly maturation of 
keratinocytes. The affected zone has grown under the epidermis and is separated from it by 
the cleft. T-cadherin is uniformly expressed in all layers of keratinocytes, including suprabasal 
layers, with a slightly increased staining in the basal cell layer (Fig.3), which correlates with 
literature data (Pfaff et al., 2010). T-cadherin expression was also verified in the dermal blood 
vessels (in endothelial and mural cells) and in the stromal cells, in the vicinity of atypical 
keratinocytes. However, not all blood vessels which were vWF positive expressed T-cadherin, 
which puts AK in line with malignant skin lesions such as squamous cells carcinoma (Fig.6).  
6.1.4 Keratoacanthoma (KA) 
Keratoacanthoma (KA) is a low-grade malignancy skin lesion with rapid growth, followed 
by a slow spontaneous resolution. KA is composed of keratinizing squamous cells 
originating in pilosebaceous follicles and histopathologically resembles squamous cells 
carcinoma (SCC) (Quinn & Perkins, 2010). However, it is well known that the morphological 
similarity between KA and SCC contrasts with their different biological behavior.  
Histologically, the squamous keratinocytes in KAs are enlarged, pale, eosinophilic, and often 
have a hyalinized or “glassy”-appearing cytoplasm. Inflammatory infiltrates are present in the 
underlying papillary dermis. While superficially infiltrative and mitotically active, especially 
in early lesions, the cells of KA generally show no pronounced atypia or cellular 
pleomorphism of conventional SCC. Atypical mitoses are not found in KA. Additionally, 
stromal desmoplasia is usually absent unlike invasive SCC, and the nests are typically 
rounded and sharply demarcated from the surrounding stroma (Cassarino et al., 2006b). 
SCC is a malignant tumor with the potential to grow, metastasize and cause death, while KA 
usually undergoes regression, thus representing a self-limiting or “biologically benign” variant 
of SCC (Zalaudek et al., 2009). KA progression could be divided into 3 phases: growth, 
stabilization and involution. The first phase is characterized by a rapid increase in size within a 
few weeks or months followed by stabilization and spontaneous resolution over 4-6 months. 
However, occasionally KA may enlarge up to 5 cm and become locally aggressive (Quinn & 
Perkins, 2010). Lesions typically begin as firm skin papules that progress to nodules with a 
central crateriform ulceration or keratin plug that may project like a horn. The histological 
features vary with the stage of evolution. The early lesion is composed of a mass of rapidly 
proliferating squamous cells. The marginal cells aggressively invade the surrounding derma, 
while those in the center keratinize to form a core of keratin that communicates with the 
surface. Resolution occurs through maturation of the hyperplastic cell masses and lesion 
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opening to the surface. When the horn is finally shed, the irregular epithelium under the lesion 
is formed. KA leaves a residual scar, if not excised (Quinn & Perkins, 2010). 
Figure 4 and Figure 5 represents KA in the stage of growth and stabilization, 
correspondingly. As a whole, our histological data indicate that the cells in KA are mature 
and the epithelium exhibit differentiation from the basal layer to the surface keratinocytes.  
 
 
Fig. 4. Double immunofluorescent staining of keratoacanthoma at the stage of growth with 
antibodies against T-cadherin (red) and vWF (green) (A). Nuclei were counterstained with 
DAPI (blue). Figure B depicts phase contrast image of the parallel section. T-cadherin 
expression was verified in all keratinocytes. Part of the blood vessels showed no T-cadherin 
expression, at the same time some of the blood vessels were found among keratinizing 
squamous cells at the site of the future pearl (A). Colocalization of T-cadherin and vWF is 
shown by the arrow, blood vessels which do not express T-cadherin are marked by 
arrowheads. Bars, 100 m. The diagram shows strong (red) and moderate (pink) T-cadherin 
expression in keratinocytes. Blood vessels expressing T-cadherin and vWF are shown in 
yellow, blood vessels with no T-cadherin expression are shown in green. 
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However, abnormal or premature keratin production (dyskeratosis) is observed resulting in 
individually keratizing cells or formation of keratin pearls (Fig.5). The stroma is vascular and 
infiltrated (Fig.4 and Fig.5). In KA T-cadherin expression was verified in all keratinocyte layers 
(Fig.4 and Fig.5). At stabilization stage of KA, T-cadherin expression was detected in all the 
surrounding blood vessels as verified by immunofluorescent staining with antibody against T-
cadherin, endothelial marker vWF and mural cell marker – actin (Fig.5). However, part of 
the blood vessels in KA at the growth stage did not express T-cadherin (Fig.4). Noteworthy, is 
the abnormal location of blood vessels within the epidermal hypertrophied layer and among 
keratinizing squamous cells at the site of the future pearl (Fig.4). The abnormal vessel location 
and down-regulated T-cadherin expression in KA at the growth stage most probably reflects 
the rapid and locally aggressive behavior of the tumor, while at stabilization stage, T-cadherin 
expression in keratinocytes and blood vessels resembles their expression in the normal skin 
samples. 
 
 
Fig. 5. Double immunofluorescent staining of keratoacanthoma at stabilization stage with 
antibodies against T-cadherin (red) and vWF (green) (A) or vWF (green) and actin (red) (C). 
Nuclei were counterstained with DAPI (blue). Figure B represents hematoxylin staining of the 
parallel section. T-cadherin expression was verified in all keratinocytes. Most of the blood 
vessels showed colocalization of vWF and T-cadherin expression, as shown by the arrows (A). 
Stabilized vessels were located in derma and were double positive for vWF and actin. Bars, 
100 m. The diagram shows strong (red) and moderate (pink) T-cadherin expression in 
keratinocytes. Blood vessels expressing T-cadherin and vWF are shown in yellow. 
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6.1.5 Basal Cell Carcinoma (BCC) 
BCC is the most common malignant tumor of the skin composed of cells originating from the 
basal cell layer of the epidermis and its appendages, namely BCCs arise from the hair follicle 
bulge stem cell or from the interfollicular epidermis (Quinn & Perkins, 2010; Wang et al., 2011). 
The typical BCC progresses slowly and rarely metastases. The early tumors are usually small, 
translucent or pearly and covered by thin epidermis. The more advanced tumors show a 
variety of forms. Some tumors grow at a very slow rate and they are in practical terms benign. 
This is true for many superficial lesions and some of the nodular types of BCCs (Quinn & 
Perkins, 2010). BCCs are truly invasive in only a small proportion of cases. Then the tumors 
show no tendency to grow as rounded masses, have no palisade or organized stroma, and 
penetrate the dermis and deeper structures, destroying them as they grow. Such tumors are 
almost always ulcerated, usually from an early stage (Quinn & Perkins, 2010). 
In the present study we examined T-cadherin expression in superficial, nodular and 
infiltrative samples of BBC. In superficial BCC, expression of T-cadherin was prominent in 
tumor cells and in the surrounding stroma. The majority of vessels around the tumor 
aggregates coexpressed markers of endothelial cells vWF and T-cadherin, however, blood 
vessels with no expression of T-cadherin were also noted (Fig. 6). 
 
 
Fig. 6. Double immunofluorescent staining of superficial BCC with antibodies against T-
cadherin (red) and vWF (green) (A). Nuclei were counterstained with DAPI (blue). Figure B 
shows hematoxylin staining of the parallel section. T-cadherin expression was observed in 
tumor cells and in the surrounding stroma. Not all blood vessels as detected by vWF 
staining were positive for T-cadherin. Colocalization of T-cadherin and vWF is shown by the  
arrows, blood vessels which do not express T-cadherin - by arrowhead. Bars, 100 m. 
The nodular BCC samples demonstrated “classic” features of basalioma, including large tumor 
nests with a smooth palisaded border and stromal retraction. In nodular BCC the expression of 
T-cadherin was heterogeneous: some tumor nests were strongly positive for T-cadherin 
expression (Fig. 7), while weak or undetectable expression of T-cadherin occurred in some 
tumor nests or individual cells within these nests (Fig. 7). These results coincide with the 
results obtained by other authors (Buechner et al., 2009), but are in contrast to data obtained by 
Takeuchi and colleagues (Takeuchi et al., 2002). Most of the blood vessels coexpressed 
endothelial cells marker vWF and T-cadherin. However, in some samples of nodular BCC, the 
aberrant expression of vessel markers and T-cadherin was revealed: in part of vWF-positive 
vessels T-cadherin expression was lost; while structures, morphologically resembling 
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Fig. 7. Double immunofluorescent staining of nodular BCCs with antibodies against T-
cadherin (red) and vWF (green) (A, D) or vWF (red) and actin (green) (C). Nuclei were 
counterstained with DAPI (blue). Figure E shows hematoxylin staining the parallel section 
of the same sample shown in Figure D; Figure B reflects phase contrast image of the parallel 
section of the same sample shown in Figures A and C. Some tumor nests were T-cadherin 
positive (A), while other nodules or individual cells within them demonstrated weak T-
cadherin expression (D). Most of the blood vessels coexpressed endothelial cells marker 
vWF and T-cadherin as shown by the arrows in A and D. However, in some samples, the 
aberrant expression of vessel markers and T-cadherin was revealed: in part of vWF-positive 
vessels T-cadherin expression was lost (arrowhead pointing to the vessels in A and D); 
while some samples structures, morphologically resembling blood vessels and expressing 
actin but vWF-negative were observed (arrowhead in C). Bars, 100 m. 
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blood vessels and expressing actin were vWF-negative (Fig. 7). In samples of infiltrating 
BCC, nests of variable size with irregular borders were detected. There was frequently little 
palisading and sometimes no stromal retraction. Tumor cells and cells of the surrounding 
stroma expressed T-cadherin, while in the blood vessels located among the stromal cells, 
aberrant vessel markers and T-cadherin was marked: in part of vWF-positive vessels T-
cadherin expression was lost (Fig. 8). While T-cadherin expression was present in 
keratinocytes in 90% of the samples, in the vessels surrounding BCC nests, its expression 
was lost in part of the blood vessels. 
 
 
Fig. 8. Double immunofluorescent staining of infiltrating BCC sample with antibodies against 
T-cadherin (red) and vWF (green) (A) or vWF (red) and actin (green) (C). Nuclei were 
counterstained with DAPI (blue). Figure B shows hematoxylin staining of the parallel section. 
T-cadherin expression was observed in tumor cells and in the surrounding stroma. In part of 
vWF-positive blood vessels located among the stromal cells T-cadherin  expression was noted 
(arrows in A). However, in some vessel-like structures aberrant expression of vessel markers 
and T-cadherin was observed: in part of vWF-positive vessels T-cadherin expression was not 
detected (arrowheads in A); while in some samples, structures, morphologically resembling 
blood vessels and expressing actin were demonstrated to be vWF-negative (arrowheads in 
C). Bars, 100 m. The diagram shows strong T-cadherin expression in red and moderate - in 
pink. Some of the tumor cells in BCC nests retain T-cadherin expression, while in the others T-
cadherin is lost. Blood vessels expressing T-cadherin and vWF are shown in yellow, blood 
vessels with no T-cadherin expression are shown in green. 
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6.1.6 Squamous Cell Carcinoma (SCC)  
A SCC of the skin is a malignant neoplasm of epidermal keratinocytes and its appendages. 
Cutaneous SCCs include many subtypes with different clinical behaviors, ranging from 
indolent to aggressive tumors with significant metastatic potential (Cassarino et al., 2006a; 
Cassarino et al., 2006b). Various classifications of SCC were proposed basing upon the 
malignant potential of SCC variants with low, intermediate or high metastatic rate (Cassarino 
et al., 2006a; Cassarino et al., 2006b; Yanofsky et al., 2011). According to the latest classification, 
histopathologically SCC can be divided into three separate categories including: actinic or 
solar keratoses (AKs) and SCC in situ (Bowen’s disease), - common precursors of SCC arising 
from excessive sun exposure; invasive SCC (SCCI), clear-cell SCC, spindle cell (sarcomatoid) 
SCC, and SCC with single cell infiltrates - tumor subtypes emerging from invasive progression 
of AKs and SCC in situ; de novo SCC, lymphoepithelioma-like carcinoma of the skin (LELCS), 
and verrucous carcinoma (VC) - very rare variants of SCC with no direct correlation to sun 
exposure or actinic neoplasms (Yanofsky et al., 2011).  
SCCIs are often referred to as conventional SCCs. SCCI are subdivided into three 
histological grades based on their associated degree of nuclear atypia and keratinization 
(well-differentiated, moderate and poorly-differentiated SCCI). The majority of SCCI’s 
arising from AKs, are well-differentiated tumors, containing slightly enlarged cells with 
hyperchromatic nuclei, which produce large amounts of keratin, resulting in the formation 
of keratin pearls. These tumors are associated with a very low malignant potential. The 
histological and cytopathological changes seen in the individual cells of AK and SCCI are 
identical. Both show atypical keratinocytes with loss of polarity, nuclear pleomorphism, 
disordered maturation and increased numbers of mitotic figures; many of them atypical and 
pleomorphic. In contrast to AK, SCCI are characterized by the presence of infiltrative cells 
passing through the basement membrane into the dermis. This infiltrate can be difficult to 
detect at the early stages of invasion, however, additional indicators such as full thickness 
epidermal atypia or the involvement of hair follicles can be used to facilitate the diagnosis. 
Later stages of invasion are characterized by the formation of nests of atypical tumor cells in 
the dermis often with inflammatory infiltrate (Yanofsky et al., 2011). 
In contrast to well-differentiated SCCI, in poor-differentiated tumors, cells are characterized 
by enlarged, pleomorphic nuclei with high degree of atypia and frequent mitosis. Keratin 
production in these cells is markedly reduced. Poorly-differentiated SCCI show deep 
infiltration of the underlying dermis and subcutaneous tissues. These SCCI demonstrate a 
much more aggressive clinical behavior, with an increased rate of metastasis and recurrence. 
A third, moderately-differentiated subtype of SCCI shares the features of both well-
differentiated and poor-differentiated tumors (Yanofsky et al., 2011). It is thought that 
poorly differentiated tumors have a higher rate of metastasis (Dinehart et al., 1997; Dinehart 
& Pollack, 1989; Lund et al., 1984). Another essential component in assessing the malignant 
potential of a tumor is the presence of perineural and perivascular spread. Invasion of 
capillaries and nerves reflects a more aggressive tumor behavior and correlates with an 
increased rate of metastases, local recurrence and disease-specific death (Yanofsky et al., 
2011). The accurate microscopy diagnostics between these variants is critically important for 
prognosis and the treatment of SCCI (Yanofsky et al., 2011). 
In our study in moderate-to-poorly-differentiated SCCI samples tumor cells deeply invaded the 
underlying dermis (Fig.9). Occasionally, some atypical cells in isolated tumor nests and stromal 
cells exhibited week T-cadherin staining. However, in basaloid cells of most of the tumor nests 
T-cadherin expression was down-regulated. The activated stroma expressed actin.  
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Fig. 9. Double immunofluorescent staining of moderate-to-poorly-differentiated SCCI 
sample with antibodies against T-cadherin (red) and vWF (green) (A) or CD31 (red) and 
actin (green) (C). Nuclei were counterstained with DAPI (blue). Figure B shows 
hematoxylin staining of the parallel section. Some atypical cells in isolated tumor nests and 
stromal cells exhibited T-cadherin staining (A), however, basaloid cells in most of the tumor 
nests show no T-cadherin expression (A). Vessel-like structures, which do not express CD31 
but exhibit actin are noted (asterisk in C), moreover, CD31-positive areas, 
morphologically different from vessels are also present (empty arrows in C). Bars, 100 m. 
The diagram marks strong T-cadherin expression in red, and moderate - in pink. In most 
tumor cells growing in small aggregates T-cadherin expression is absent. Blood vessels 
expressing T-cadherin  and vWF are shown in yellow, blood vessels with no T-cadherin 
expression are shown in green. Vessel-like structures expressing actin are shown in violet. 
This data correlate with results obtained by other authors (Mykoyama et al., 2005; Pfaff et 
al., 2010; Takeuchi et al., 2002b; Zhou et al., 2003) and indicate that T-cadherin loss due to 
aberrant methylation of the T-cadherin gene or its deletion correlates with SCC invasive 
phenotype and potentially more aggressive tumor behavior. 
However, our results demonstrated that in SCCI not only T-cadherin expression was lost in 
atypical keratinocytes. Among other abnormalities the aberrant expression of vessel markers 
and T-cadherin was noted: in part of vWF-positive vessels T-cadherin expression was lost; at 
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the same time, we observed vessel-like structures, which did not express vWF but bear T-
cadherin or actin. Strikingly, CD31/vWF-positive areas, morphologically different from 
vessels were also noted (Fig.9). 
6.1.7 Basosquamous Cell Carcinoma (BSCC) or metatypical basal cell carcinoma  
The term basosquamous cell carcinoma is used for tumors that exhibit the features of both 
BCC and SCC (Garcia et al., 2009). BSCC is not widely discussed in the literature and little 
attention has been paid to this subtype in recent comprehensive reviews of cutaneous SCC 
(Cassarino et al., 2006a; Cassarino  et al., 2006b). The importance of diagnostics of these 
tumors is based on the fact that BSCC pathological pattern is associated with a more 
aggressive behavior and a significantly higher incidence of metastasis than BCC or SCC 
(Banks et al., 1992; Farmer & Helwig, 1980; Smith & Irons, 1983; Winzenburg et al., 1998). 
The diagnosis of BSCC is currently based on histological criteria, initially proposed by Wain 
and coauthors (Wain et al., 1986). BSCCs are characterized by exaggerated nuclear to 
cytoplasmic ratio of the tumor nests which results in their basaloid appearance. Atypical 
mitotic figures can be readily visualized (Zbären et al., 2004; Boyd et al., 2011). The cells are 
larger with a larger paler nucleus than in the classic BCC and have a more eosinophilic 
cytoplasm (Quinn & Perkins, 2010). The BSCC is characterized by cell aggregates lacking 
classical palisading of BCC and embedded in a dense and profound fibrous stroma. The 
surrounding stroma is fibrotic with occasional deposits of hyaline basement membrane in 
the form of the extracellular material adjacent to tumor aggregates (Sarbia et al., 1997; 
Zbären et al., 2004).  
Figure 10 presents representative patterns of immunostaining of BSCC with antibodies against 
T-cadherin, endothelial cell marker vWF and smooth muscle/pericyte cell marker actin. 
Tumor cells formed aggregates of different size, which generally lacked T-cadherin expression; 
however, in some cells at the periphery of these aggregates T-cadherin expression was still 
observed (Fig. 10). Tumor masses were surrounded by stroma expressing T-cadherin (Fig.10). 
The majority of vessels around the tumors aggregates coexpressed markers of endothelial cells 
- vWF and T-cadherin or vWF and actin (Fig. 10), thus resembling capillaries and stable 
blood vessels of the normal skin (Fig. 10). However, structures morphologically resembling 
blood vessels and expressing T-cadherin or actin, but lacking expression of classical 
endothelial marker vWF was noted (Fig. 10). Alternatively, vWF-positive vessels with no 
expression of T-cadherin were observed (data not shown).  
To summarize, the obtained data confirm the fact that the initially occasional loss of T-
cadherin expression in keratinocytes and blood vessels of pre-malignant lesions but 
subsequently progressive down-regulation of T-cadherin expression in tumor cells, 
appearance of blood vessels aberrantly expressing T-cadherin and endothelial/mural cell 
markers of more aggressive tumors correlate with the malignant transformation of the skin 
neoplasms.  
7. Conclusion 
The presented data support the statement that the loss of T-cadherin expression in 
epidermal keratinocytes is biologically relevant to malignant transformation of normal 
epidermal cells into cancer and correlates with the literature data. It has been proposed that 
T-cadherin expression may contribute to maintenance of tissue integrity in resting  
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Fig. 10. Double immunofluorescent staining of BSCCs sample with antibodies against T-
cadherin (red) and vWF (green) (A) or CD31 (red) and actin (green) (C). Nuclei were 
counterstained with DAPI (blue). Figure B shows hematoxylin staining of the parallel 
section. Tumor cells formed aggregates of different size, which generally lacked T-cadherin 
expression, however, in some tumor nests or in cells at the periphery of tumor aggregates T-
cadherin expression is still observed (A). The majority of vessels around the tumor 
aggregates coexpressed markers of endothelial cells - vWF and T-cadherin (arrows in A) or 
vWF and actin (C). However, aberrant expression of vessel markers and T-cadherin could 
be seen: vessel-like T-cadherin positive structures with no expression of vWF are marked by 
empty arrow in B and actin vessel-like structures with no expression of CD31 by asterisk 
in C. The diagram marks strong T-cadherin expression in red, and moderate - in pink. In 
most tumor cells growing in small aggregates T-cadherin expression is absent. Blood vessels 
expressing T-cadherin and vWF are shown in yellow, blood vessels with no T-cadherin 
expression are shown in green. Vessel-like structures expressing actin are shown in violet. 
conditions by preventing cell dislocation (Ivanov et al, 2003), that’s why T-cadherin 
expression is well marked in the basal layer of keratinocytes attached to the basal membrane 
and bordering with underlying derma.  
In the normal skin proliferation takes place in the basal layer of keratinocytes which 
correlates with the maximal T-cadherin expression in these cells. Interestingly, upon 
maturation epidermal keratinocyte are moved from the basal cell layer towards skin surface 
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not crossing the layer with the maximal T-cadherin expression. In pre-malignant skin 
lesions such as KA at stabilization stage, psoriasis, AK and superficial basalioma, which 
demonstrate slow or controlled growth and, in most cases, where keratinocytes maintain 
interactions with the basal membrane, the pattern of T-cadherin expression partly resembles 
that in the normal skin. Upon tumorigenesis in some BSCCs, SCCs, and in some cases of 
BCC, when tumors are characterized by a higher proliferative, invasive and metastatic 
potential, keratinocytes tend to grow in smaller cell aggregates and down-regulate T-
cadherin expression. It is tempting to speculate that T-cadherin acts as a tumor suppressor 
in the normal skin and pre-malignant lesions by restricting keratinocyte proliferation and 
migration and by enhancing their homophilic interactions within the cell layer. In cancer, 
aggressive behavior of tumor cells correlates with the loss of T-cadherin expression.  
In normal skin samples and in pre-malignant lesions such as psoriasis, KA at stabilization 
stage and superficial BCC all blood vessels uniformly express endothelial cells marker vWF 
and T-cadherin. Although AK in some papers is regarded as premalignant skin lesion, we 
revealed that in AK not all vWF-positive blood vessels expressed T-cadherin. This puts AK 
in line with malignant skin lesions such as SCC where T-cadherin is partly lost from the 
blood vessels. In KA at the growing stage part of the blood vessels do not express T-
cadherin and grow into the layer of hypertrophied and rapidly proliferating keratinocytes, 
which reflects the aggressive behavior of this tumor at the stage of the fast growth. In cancer 
samples such as BSCC, BCC or SCC we observed heterogeneity in the expression of vascular 
markers (vWF and smooth muscle/pericyte cell marker actin) and T-cadherin. Thus, 
aberrant expression of classical vascular markers and heterogeneity in T-cadherin 
expression in tumor vasculature correlates with the histological features and invasive 
behavior of more aggressive tumors such as BSCC, BCC or SCC.  
We propose that high expression of T-cadherin in normal tissue and in benign tumors 
prevents the excessive ingrowth of blood vessels that also express T-cadherin. During the 
tumor transformation, expression of T-cadherin on vascular endothelial cells is disturbed, 
and this causes abnormality in vascularization of tumor nodules and surrounding stroma.  
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